recurrent breast cancer
Showing 1 - 25 of >10,000
Toxicities of Salvage Treatment in Locoregionally Recurrent
Not yet recruiting
- Breast Cancer
- Salvage treatment (surgery and/or radiation therapy)
-
Seoul, Korea, Republic ofSamsung Medical Center
Jul 5, 2023
Breast Cancer, Recurrent Trial in Meldola (Partial breast re-irradiation)
Not yet recruiting
- Breast Cancer
- Recurrent
- Partial breast re-irradiation
-
Meldola, Forlì Cesena, ItalyUO Radioterapia, IRST IRCCS
Mar 6, 2023
Breast Cancer Trial in Beijing (Drug: 68Ga-P16-093)
Recruiting
- Breast Cancer
- Drug: 68Ga-P16-093
-
Beijing, ChinaPeking Union Medical College Hospital
Nov 14, 2022
Breast Cancer Stage IIB Trial in Philadelphia (Hydroxychloroquine, Everolimus)
Recruiting
- Breast Cancer Stage IIB
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 8, 2022
Breast Cancer Trial in United Kingdom (Hydrogen Peroxide)
Recruiting
- Breast Cancer
- Hydrogen Peroxide
-
Lucknow, Uttar Pradesh, India
- +7 more
Sep 21, 2022
Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)
Not yet recruiting
- Breast Cancer
- (no location specified)
Apr 3, 2023
HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,
Not yet recruiting
- HER2-PositiveRecurrent or Metastatic Breast Cancer
- SHR-A1811 Injection
- +2 more
- (no location specified)
Sep 21, 2023
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer Trial in
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +9 more
- anastrozole
- +3 more
-
Boston, Massachusetts
- +1 more
Sep 9, 2022
Breast Cancer Female, Breast Cancer Recurrent Trial in Drammen (18F-FDG PET/CT)
Recruiting
- Breast Cancer Female
- Breast Cancer Recurrent
- 18F-FDG PET/CT
-
Drammen, NorwayDrammen Hospital - Vestre Viken HF
Feb 17, 2023
Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)
Not yet recruiting
- Breast Neoplasms
- Sindilimab
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiangCH
Nov 17, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
PET/CT Parameters and Tumor Markers in Recurrent Breast Cancer
Not yet recruiting
- Breast Cancer
- PET/CT
- (no location specified)
Sep 30, 2021
Advanced or Recurrent Breast Cancer Trial in Japan (Entinostat, Entinostat(Placebo), Exemestane)
Completed
- Advanced or Recurrent Breast Cancer
- Entinostat
- +2 more
-
Nagoya, Aichi, Japan
- +27 more
Jun 15, 2022
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)
Not yet recruiting
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- KN026
- +4 more
- (no location specified)
Apr 20, 2023
HER2-positive Breast Cancer Trial in Chengdu (Recombinant anti-HER2 humanized mAb conjugate for injection.R&D code: B003.)
Active, not recruiting
- HER2-positive Breast Cancer
- Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.
-
Chengdu, Sichuan, ChinaWest China Hospital of Sichuan University
Jan 30, 2023
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma Trial in Boston,
Active, not recruiting
- Estrogen Receptor-positive Breast Cancer
- +5 more
- PI3K inhibitor BYL719
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 14, 2022
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer Trial in London (Palbociclib, Avelumab)
Recruiting
- Triple Negative Breast Cancer
- +5 more
-
Manchester, Greater Manchester, United Kingdom
- +6 more
Jan 5, 2023
Edema, Erythema, Estrogen Receptor Negative Trial in Houston (Laboratory Biomarker Analysis, Pembrolizumab)
Active, not recruiting
- Edema
- +8 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Jan 23, 2023
Omitting Axillary Surgery in Breast Cancer Isolated Chest Wall
Recruiting
- Breast Cancer
- Recurrent Disease
- axillary surgery
-
Singapore, SingaporeKK Women's and Children's Hospital
Oct 12, 2023
Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)
Recruiting
- Triple Negative Breast Cancer
- Eribulin Mesylate
- Lobaplatin
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022
LYNPARZA Breast Cancer in Adjuvant Setting Japan Post-Marketing
Not yet recruiting
- Breast Cancer
- (no location specified)
Jan 9, 2023